ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-PD-1/Anti-VEGF Bispecific Antibody JS207

Also written as “WJB001 Capsules+Paclitaxel+carboplatin+JS207/Toripalimab” and “JS207”.

Its studies are led by 2 companies.

Drug pageAnti-PD-1/Anti-VEGF Bispecific Antibody JS207: every studyAll 12 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 2, since Mar 8, 20262 company-led studies, 2 open or runningNext primary completion: Dec 31, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Mabwell (Shanghai) Bioscienceits history only11 open or runningphase 2since Mar 8, 2026Mar 8, 2026Dec 31, 2027phase 2 · NCT07466160
Wigen Biomedicine Technology (Shanghai)its history only11 open or runningphase 2since Apr 23, 2025Apr 23, 2025Jun 30, 2029phase 2 · NCT06953323

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of every company. Pick one to see its own:

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 23, 2025First study: phase 2 study in Advanced Solid TumorNew to Wigen Biomedicine Technology (Shanghai)Wigen Biomedicine Technology (Shanghai) · NCT06953323 · 86 planned · China
  2. Mar 8, 2026Mabwell (Shanghai) Bioscience’s first study: phase 2 study in Solid TumorNew to Mabwell (Shanghai) BioscienceMabwell (Shanghai) Bioscience · NCT07466160 · 280 planned · China

Ahead

  1. Dec 31, 2027Primary completion: phase 2 study in Solid TumorMabwell (Shanghai) Bioscience · NCT07466160
  2. Jun 30, 2029Primary completion: phase 2 study in Advanced Solid TumorWigen Biomedicine Technology (Shanghai) · NCT06953323

TargetBeta

PDCD1 →VEGFA →read by rule
“A recombinant humanized bispecific antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and the human vascular endothelial growth factor (VEGF), ”NCIt, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
ivonescimabruleAkesophase 348
tivunatamigPfizerphase 315
Anti-PD-1/Anti-VEGF Bispecific Antibody SCTB14ruleSinocelltech Groupphase 32
ABBV-1480RemeGenphase 32
Anti-PD-1/Anti-VEGF-A Bispecific Antibody CR-001ruleSichuan Kelun Pharmaceuticalphase 24
Anti-PD-1/Anti-VEGF Bispecific Antibody MK-2010Merckphase 24
Anti-PD-1/Anti-VEGF Bispecific Antibody MHB039AruleMinghui Pharmaceuticalphase 23
Anti-PD-1/Anti-CTLA-4/Anti-VEGF Trispecific Antibody HC010rulehc-biopharma-incphase 22
Anti-PD-1/Anti-VEGF-A Bispecific Antibody CTX-10726rulecompass-therapeuticsphase 11

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07466160Solid Tumor · China2RecruitingMabwell (Shanghai) BioscienceDec 31, 2027280
NCT06953323Advanced Solid Tumor · China2RecruitingWigen Biomedicine Technology (Shanghai)Jun 30, 202986

How it is read

Names in the registry

  • “WJB001 Capsules+Paclitaxel+carboplatin+JS207/Toripalimab”, 1 entry
  • “JS207”, 1 entry

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.